Build Your Comparison

Side-by-side financial analysis
BMEA logo
BMEA
NTRA logo
NTRA
JPM logo
JPM
Try popular comparisons:

Stock Comparison

BMEA vs NTRA vs JPM

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
BMEA
Biomea Fusion, Inc.

Biotechnology

HealthcareNASDAQ • US
Market Cap$70M
5Y Perf.-93.1%
NTRA
Natera, Inc.

Medical - Diagnostics & Research

HealthcareNASDAQ • US
Market Cap$30.37B
5Y Perf.+92.8%
JPM
JPMorgan Chase & Co.

Banks - Diversified

Financial ServicesNYSE • US
Market Cap$896.00B
5Y Perf.+108.5%

BMEA vs NTRA vs JPM — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
BMEA logoBMEA
NTRA logoNTRA
JPM logoJPM
IndustryBiotechnologyMedical - Diagnostics & ResearchBanks - Diversified
Market Cap$70M$30.37B$896.00B
Revenue (TTM)$0.00$2.50B$280.33B
Net Income (TTM)$-45M$-226M$57.05B
Gross Margin65.2%60.0%
Operating Margin-13.0%25.9%
Forward P/E14.4x
Total Debt$2M$214M$942.38B
Cash & Equiv.$56M$1.08B$343.34B

BMEA vs NTRA vs JPMLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

BMEA
NTRA
JPM
StockApr 21Jun 26Return
Biomea Fusion, Inc. (BMEA)1006.9-93.1%
Natera, Inc. (NTRA)100192.8+92.8%
JPMorgan Chase & Co. (JPM)100208.5+108.5%

Price return only. Dividends and distributions are not included.

Quick Verdict: BMEA vs NTRA vs JPM

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: JPM leads in 5 of 7 categories, making it the strongest pick for valuation and capital efficiency and profitability and margin quality. Biomea Fusion, Inc. is the stronger pick specifically for growth and revenue expansion. This set spans 2 sectors — these stocks serve different portfolio roles, not just different price points.
🥇JPM emerged as the overall leader. Track its performance:
BMEA
Biomea Fusion, Inc.
The Defensive Pick

BMEA is the clearest fit if your priority is sleep-well-at-night.

  • Lower volatility, beta 1.78, Low D/E 5.4%, current ratio 5.23x
  • 65.4% revenue growth vs JPM's 3.3%
Best for: sleep-well-at-night
NTRA
Natera, Inc.
The Growth Play

NTRA is the clearest fit if your priority is growth exposure and long-term compounding.

  • Rev growth 35.9%, EPS growth 0.7%, 3Y rev CAGR 41.1%
  • 17.3% 10Y total return vs JPM's 465.8%
  • +29.0% vs BMEA's -55.2%
Best for: growth exposure and long-term compounding
JPM
JPMorgan Chase & Co.
The Banking Pick

JPM carries the broadest edge in this set and is the clearest fit for income & stability and defensive.

  • Dividend streak 15 yrs, beta 0.94, yield 1.9%
  • Beta 0.94, yield 1.9%, current ratio 0.52x
  • Better valuation composite
Best for: income & stability and defensive
See the full category breakdown
CategoryWinnerWhy
GrowthBMEA logoBMEA65.4% revenue growth vs JPM's 3.3%
ValueJPM logoJPMBetter valuation composite
Quality / MarginsJPM logoJPM20.4% margin vs NTRA's -9.0%
Stability / SafetyJPM logoJPMBeta 0.94 vs BMEA's 1.78
DividendsJPM logoJPM1.9% yield; 15-year raise streak; the other 2 pay no meaningful dividend
Momentum (1Y)NTRA logoNTRA+29.0% vs BMEA's -55.2%
Efficiency (ROA)JPM logoJPM1.3% ROA vs BMEA's -77.1%

BMEA vs NTRA vs JPM — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

Discover the Biotech & Healthcare Stocks Theme

These companies are key players in the Biotech & Healthcare Stocks ecosystem. See how they stack up against the rest of the sector.

Explore Theme
BMEABiomea Fusion, Inc.

Segment breakdown not available.

NTRANatera, Inc.
FY 2025
Product
99.6%$2.3B
Licensing and other
0.4%$10M
JPMJPMorgan Chase & Co.
FY 2025
Commercial And Investment Bank
43.0%$78.5B
Consumer & Community Banking
41.7%$76.0B
Asset and Wealth Management Segment
13.2%$24.1B
Segment Reporting, Reconciling Item, Corporate Nonsegment
3.9%$7.0B
Segment Reconciling Items
-1.7%$-3,134,000,000

BMEA vs NTRA vs JPM — Financial Metrics

Side-by-side numbers across 3 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLJPMLAGGINGBMEA

Income & Cash Flow (Last 12 Months)

JPM leads this category, winning 3 of 5 comparable metrics.

JPM and BMEA operate at a comparable scale, with $280.3B and $0 in trailing revenue. JPM is the more profitable business, keeping 20.4% of every revenue dollar as net income compared to NTRA's -9.0%.

MetricBMEA logoBMEABiomea Fusion, In…NTRA logoNTRANatera, Inc.JPM logoJPMJPMorgan Chase & …
RevenueTrailing 12 months$0$2.5B$280.3B
EBITDAEarnings before interest/tax-$66M-$313M$81.4B
Net IncomeAfter-tax profit-$45M-$226M$57.0B
Free Cash FlowCash after capex-$56M$92M$100.9B
Gross MarginGross profit ÷ Revenue+65.2%+60.0%
Operating MarginEBIT ÷ Revenue-13.0%+25.9%
Net MarginNet income ÷ Revenue-9.0%+20.4%
FCF MarginFCF ÷ Revenue+3.7%+36.0%
Rev. Growth (YoY)Latest quarter vs prior year+38.8%
EPS Growth (YoY)Latest quarter vs prior year+78.8%-20.0%+16.0%
JPM leads this category, winning 3 of 5 comparable metrics.

Valuation Metrics

JPM leads this category, winning 2 of 4 comparable metrics.
MetricBMEA logoBMEABiomea Fusion, In…NTRA logoNTRANatera, Inc.JPM logoJPMJPMorgan Chase & …
Market CapShares × price$70M$30.4B$896.0B
Enterprise ValueMkt cap + debt − cash$15M$29.5B$1.50T
Trailing P/EPrice ÷ TTM EPS-0.99x-139.52x16.00x
Forward P/EPrice ÷ next-FY EPS est.14.40x
PEG RatioP/E ÷ EPS growth rate0.90x
EV / EBITDAEnterprise value multiple18.36x
Price / SalesMarket cap ÷ Revenue13.17x3.20x
Price / BookPrice ÷ Book value/share2.07x16.93x2.47x
Price / FCFMarket cap ÷ FCF278.35x8.88x
JPM leads this category, winning 2 of 4 comparable metrics.

Profitability & Efficiency

JPM leads this category, winning 6 of 9 comparable metrics.

JPM delivers a 15.9% return on equity — every $100 of shareholder capital generates $16 in annual profit, vs $-197 for BMEA. BMEA carries lower financial leverage with a 0.05x debt-to-equity ratio, signaling a more conservative balance sheet compared to JPM's 2.60x. On the Piotroski fundamental quality scale (0–9), NTRA scores 5/9 vs BMEA's 3/9, reflecting solid financial health.

MetricBMEA logoBMEABiomea Fusion, In…NTRA logoNTRANatera, Inc.JPM logoJPMJPMorgan Chase & …
ROE (TTM)Return on equity-196.7%-15.1%+15.9%
ROA (TTM)Return on assets-77.1%-10.4%+1.3%
ROICReturn on invested capital-36.1%+4.5%
ROCEReturn on capital employed-153.8%-18.3%+8.9%
Piotroski ScoreFundamental quality 0–9355
Debt / EquityFinancial leverage0.05x0.13x2.60x
Net DebtTotal debt minus cash-$54M-$862M$599.0B
Cash & Equiv.Liquid assets$56M$1.1B$343.3B
Total DebtShort + long-term debt$2M$214M$942.4B
Interest CoverageEBIT ÷ Interest expense-34.29x0.74x
JPM leads this category, winning 6 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

NTRA leads this category, winning 4 of 6 comparable metrics.

A $10,000 investment in JPM five years ago would be worth $21,820 today (with dividends reinvested), compared to $569 for BMEA. Over the past 12 months, NTRA leads with a +29.0% total return vs BMEA's -55.2%. The 3-year compound annual growth rate (CAGR) favors NTRA at 62.4% vs BMEA's -69.2% — a key indicator of consistent wealth creation.

MetricBMEA logoBMEABiomea Fusion, In…NTRA logoNTRANatera, Inc.JPM logoJPMJPMorgan Chase & …
YTD ReturnYear-to-date-12.7%-7.3%-0.5%
1-Year ReturnPast 12 months-55.2%+29.0%+21.8%
3-Year ReturnCumulative with dividends-97.1%+328.7%+138.2%
5-Year ReturnCumulative with dividends-94.3%+104.4%+118.2%
10-Year ReturnCumulative with dividends-93.1%+1731.3%+465.8%
CAGR (3Y)Annualised 3-year return-69.2%+62.4%+33.6%
NTRA leads this category, winning 4 of 6 comparable metrics.

Risk & Volatility

JPM leads this category, winning 2 of 2 comparable metrics.

JPM is the less volatile stock with a 0.94 beta — it tends to amplify market swings less than BMEA's 1.78 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. JPM currently trades 95.1% from its 52-week high vs BMEA's 38.0% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricBMEA logoBMEABiomea Fusion, In…NTRA logoNTRANatera, Inc.JPM logoJPMJPMorgan Chase & …
Beta (5Y)Sensitivity to S&P 5001.78x1.24x0.94x
52-Week HighHighest price in past year$3.08$256.36$337.25
52-Week LowLowest price in past year$0.87$131.81$262.71
% of 52W HighCurrent price vs 52-week peak+38.0%+82.7%+95.1%
RSI (14)Momentum oscillator 0–10038.255.959.1
Avg Volume (50D)Average daily shares traded1.5M1.4M7.0M
JPM leads this category, winning 2 of 2 comparable metrics.

Analyst Outlook

Insufficient data to determine a leader in this category.

Analyst consensus: BMEA as "Buy", NTRA as "Buy", JPM as "Buy". Consensus price targets imply 1626.5% upside for BMEA (target: $20) vs 5.9% for JPM (target: $340). JPM is the only dividend payer here at 1.86% yield — a key consideration for income-focused portfolios.

MetricBMEA logoBMEABiomea Fusion, In…NTRA logoNTRANatera, Inc.JPM logoJPMJPMorgan Chase & …
Analyst RatingConsensus buy/hold/sellBuyBuyBuy
Price TargetConsensus 12-month target$20.20$261.00$339.75
# AnalystsCovering analysts132761
Dividend YieldAnnual dividend ÷ price+1.9%
Dividend StreakConsecutive years of raises15
Dividend / ShareAnnual DPS$5.95
Buyback YieldShare repurchases ÷ mkt cap0.0%0.0%+3.9%
Insufficient data to determine a leader in this category.
Key Takeaway

JPM leads in 4 of 6 categories (Income & Cash Flow, Valuation Metrics). NTRA leads in 1 (Total Returns).

Best OverallJPMorgan Chase & Co. (JPM)Leads 4 of 6 categories
Loading custom metrics...

BMEA vs NTRA vs JPM: Key Questions Answered

9 questions · data-driven answers · updated daily

01

Is BMEA or NTRA or JPM a better buy right now?

For growth investors, Natera, Inc.

(NTRA) is the stronger pick with 35. 9% revenue growth year-over-year, versus 3. 3% for JPMorgan Chase & Co. (JPM). JPMorgan Chase & Co. (JPM) offers the better valuation at 16. 0x trailing P/E (14. 4x forward), making it the more compelling value choice. Analysts rate Biomea Fusion, Inc. (BMEA) a "Buy" — based on 13 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which is the better long-term investment — BMEA or NTRA or JPM?

Over the past 5 years, JPMorgan Chase & Co.

(JPM) delivered a total return of +118. 2%, compared to -94. 3% for Biomea Fusion, Inc. (BMEA). Over 10 years, the gap is even starker: NTRA returned +1731% versus BMEA's -93. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

03

Which is safer — BMEA or NTRA or JPM?

By beta (market sensitivity over 5 years), JPMorgan Chase & Co.

(JPM) is the lower-risk stock at 0. 94β versus Biomea Fusion, Inc. 's 1. 78β — meaning BMEA is approximately 88% more volatile than JPM relative to the S&P 500. On balance sheet safety, Biomea Fusion, Inc. (BMEA) carries a lower debt/equity ratio of 5% versus 3% for JPMorgan Chase & Co. — giving it more financial flexibility in a downturn.

04

Which is growing faster — BMEA or NTRA or JPM?

By revenue growth (latest reported year), Natera, Inc.

(NTRA) is pulling ahead at 35. 9% versus 3. 3% for JPMorgan Chase & Co. (JPM). On earnings-per-share growth, the picture is similar: Biomea Fusion, Inc. grew EPS 69. 2% year-over-year, compared to 0. 7% for Natera, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

05

Which has better profit margins — BMEA or NTRA or JPM?

JPMorgan Chase & Co.

(JPM) is the more profitable company, earning 20. 4% net margin versus -9. 0% for Natera, Inc. — meaning it keeps 20. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: JPM leads at 26. 0% versus -13. 4% for NTRA. At the gross margin level — before operating expenses — NTRA leads at 64. 8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

06

Is BMEA or NTRA or JPM more undervalued right now?

Analyst consensus price targets imply the most upside for BMEA: 1626.

5% to $20. 20.

07

Which pays a better dividend — BMEA or NTRA or JPM?

In this comparison, JPM (1.

9% yield) pays a dividend. BMEA, NTRA do not pay a meaningful dividend and should not be held primarily for income.

08

Is BMEA or NTRA or JPM better for a retirement portfolio?

For long-horizon retirement investors, JPMorgan Chase & Co.

(JPM) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 94), 1. 9% yield, +465. 8% 10Y return). Biomea Fusion, Inc. (BMEA) carries a higher beta of 1. 78 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (JPM: +465. 8%, BMEA: -93. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

09

What are the main differences between BMEA and NTRA and JPM?

These companies operate in different sectors (BMEA (Healthcare) and NTRA (Healthcare) and JPM (Financial Services)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: BMEA is a small-cap quality compounder stock; NTRA is a mid-cap high-growth stock; JPM is a large-cap deep-value stock. JPM pays a dividend while BMEA, NTRA do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.